Lycia Therapeutics To Present At The 2026 Jefferies Global Healthcare Conference
A live webcast of the presentation may be accessed in the Investors section of the Lycia Therapeutics website at ir.lyciatx.com. A replay of the webcast will be available for approximately 60 days following the presentation.
About Lycia Therapeutics
Lycia Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company has advanced its proprietary LYTAC (Lysosomal Targeting Chimera) platform to generate cataLYTACTM degraders, which are designed for repeated catalytic elimination of disease-causing proteins. The company's lead candidates include LCA-0061, a cataLYTACTM degrader of IgE for food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies that cause Graves' disease.
Lycia, headquartered in South San Francisco, was founded on the transformational work of Nobel laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University.
For more information, please visit and follow us on LinkedIn.
Investor Contact:
Amy Bachrodt, Lycia Therapeutics
...
Media Contact:
Jennifer Price, The Grace Group
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment